MEDRELEAF CORP COM NPV (OTCMKTS:MEDFF) is a value play in the cannabis field. MEDFF is a Canadian cannabis purveyor that went public not long ago dealing with high-end cannabis. MEDFF is focused cannabis oils, which have a higher price point and better margin than traditional dried cannabis products. As of the fourth quarter of 2016, MedReleaf had a 44.5% share of the Canadian cannabis oils market.
A review of the company’s bottom line on SEDAR shows that MedReleaf earned $8.72 million in net income in fiscal 2017, up substantially from the $2.02 million profit it recorded in 2016 and nominal loss it generated in 2015. Taking into account the number of shares outstanding, MedReleaf earned about $0.156 per share in full-year 2017, which works out to a trailing 12-month P/E of just under 41. OK, so 41 isn’t exactly value stock territory in the normal definition of the word, but it is when sales of the company more than doubled in fiscal 2017.
MEDRELEAF CORP COM NPV (OTCMKTS:MEDFF), according to the company, sets The Medical Grade Standard for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified producer of cannabis-based pharmaceutical products in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
Find out when $MEDFF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Shortly after going public, MEDFF announced a milestone achievement with the completion of its first international export. The transaction is also noteworthy as the first ever import of medical cannabis oil to Brazil and serves as a demonstration of both the Company’s commitment to international growth and to establishing its position as the leading source of cannabis-based pharmaceutical products globally. Neil Closner, CEO of MedReleaf Commented:“This is an important step in achieving MedReleaf’s goals of ensuring that patients in need around the world receive the highest quality cannabis-based pharmaceutical products available and in realizing our long-term growth plans.”
In the last six months, MEDFF has gone from $0.44 to .70. As Canada moves closer and closer to full legalization, MEDFF should be on your radar.
MEDRELEAF CORP COM NPV (OTCMKTS:MEDFF) is sporting a 771.99M market cap and rapidly growing. Investors may not want to wait if they are interested in this company because it is getting press all over the wire. The discount may not last forever. Sign-up for continuing coverage on shares of $MEDFF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $MEDFF, either long or short, and we have not been compensated for this article.